Home / Products / Genome-edited Cells / PER2 Knockout H4 Cell Line

PER2 Knockout H4 Cell Line

Cat. No. ARG0250
Product Type:

Genome-edited Cells

Tissue Source:

Brain

In stock
Request a Quote

Short Description 🔒

The PER2 Knockout H4 Cell Line is a CRISPR/Cas9-edited human neuroglioma cell line with targeted disruption of PER2, a core circadian clock gene encoding a transcriptional repressor. PER2 operates in the negative feedback loop, forming inhibitory complexes with CRY1 and CRY2 to repress CLOCK-BMAL1-driven transcription. This knockout model is designed for circadian research in a glial cell context, enabling studies on clock-regulated gene expression, glial biology, chronotherapy, and circadian disruption in cancer. Typical applications include luciferase reporter assays, RT-qPCR, western blotting, immunofluorescence, and drug sensitivity analyses.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Genome-edited Cells
Tissue Source:
Brain
Disease:
Astrocytoma
Morphology:
Epithelial-like
Age:
37 years
Sex of Donor:
Male
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice

Cell Engineering Information

Host Cell:
H4
Gene Name:
PER2
Gene Identifier:
NCBI Gene ID 8864
Gene Species:
Homo sapiens (Human)

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Pathogens:
Cells tested negative for HIV-1, HBV, and HCV.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The PER2 Knockout H4 Cell Line is a CRISPR/Cas9-edited knockout cell line based on H4 human neuroglioma cells. It features a targeted disruption of PER2, generating a stable loss-of-function model for circadian clock studies. This CRISPR/Cas9-mediated gene disruption eliminates PER2 protein expression, enabling functional dissection without off-target effects of transient methods. The line is optimized for complementation assays and signaling pathway analysis.

The H4 cell line was established from a human brain glioma and retains glial cell characteristics, including support and insulation functions for neurons. H4 cells are widely used for glial biology and brain tumor research due partly to their robust growth and genetic manipulability, making them ideal for CRISPR-based circadian gene knockout.

PER2 acts as a transcriptional repressor in the circadian negative feedback loop. It is transcriptionally induced by CLOCK-BMAL1 heterodimers, phosphorylated by CK1??/?? and GSK3??, and then forms complexes with CRY1/CRY2. These PER-CRY complexes translocate to the nucleus to inhibit CLOCK-BMAL1-mediated transcription of clock genes (PER1, CRY, DBP) and cell cycle regulators. Additional interacting factors include TIMELESS and CK1??/??, linking PER2 to diverse physiological rhythms.

The H4 neuroglioma background makes this line particularly valuable for dissecting glial circadian biology. Astrocytic clocks regulate synaptic activity, metabolic coupling, and neuroinflammation. PER2 disruption in H4 cells thus enables exploration of glial clock dysfunction in glioma progression, sleep disorders, and metabolic imbalances. Moreover, glial circadian disruption may influence drug metabolism and chronotherapeutic outcomes, expanding application to neuropharmacology.

This knockout line supports diverse assays: real-time bioluminescent recording of circadian dynamics via luciferase reporters, RT-qPCR profiling of rhythmic gene expression, western blotting for PER2 and phosphorylation variants, and immunofluorescence for subcellular localization. Co-immunoprecipitation can be performed to study PER2-CRY1/2 complexes, and flow cytometry enables cell cycle analysis. Drug sensitivity testing facilitates chronotherapeutic investigations, and overexpressing mutant PER2 models sleep phase syndromes. For further information, please contact Ascent Research.